Brown JE - Search Results

1

Assessment of the impact of targeted therapy on metastatic bone disease in renal cancer.

Brown JE, Wood SL. Brown JE, et al. Eur Urol. 2014 Sep;66(3):510-1. doi: 10.1016/j.eururo.2014.03.042. Epub 2014 Apr 13. Eur Urol. 2014. PMID: 24746971 No abstract available.

2

Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer.

Smith MR, Cook RJ, Coleman R, Brown J, Lipton A, Major P, Hei YJ, Saad F. Smith MR, et al. Urology. 2007 Aug;70(2):315-9. doi: 10.1016/j.urology.2007.03.071. Urology. 2007. PMID: 17826496 Free PMC article. Clinical Trial.

3

The use of bone markers in a 6-week study to assess the efficacy of oral clodronate in patients with metastatic bone disease.

Brown JE, McCloskey EV, Dewar JA, Body JJ, Cameron DA, Harnett AN, Ruutu M, Purohit OP, Tähtelä R, Coleman RE. Brown JE, et al. Calcif Tissue Int. 2007 Nov;81(5):341-51. doi: 10.1007/s00223-007-9061-x. Epub 2007 Sep 18. Calcif Tissue Int. 2007. PMID: 17874331 Clinical Trial.

4

Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer.

Lester JE, Dodwell D, Purohit OP, Gutcher SA, Ellis SP, Thorpe R, Horsman JM, Brown JE, Hannon RA, Coleman RE. Lester JE, et al. Among authors: brown je. Clin Cancer Res. 2008 Oct 1;14(19):6336-42. doi: 10.1158/1078-0432.CCR-07-5101. Clin Cancer Res. 2008. PMID: 18829518 Clinical Trial.

5

Prognostic factors for skeletal complications from metastatic bone disease in breast cancer.

Brown JE, Cook RJ, Lipton A, Costa L, Coleman RE. Brown JE, et al. Breast Cancer Res Treat. 2010 Oct;123(3):767-79. doi: 10.1007/s10549-010-0981-1. Epub 2010 Jun 24. Breast Cancer Res Treat. 2010. PMID: 20574672

6

Medical management of metastatic bone disease.

Vasudev NS, Brown JE. Vasudev NS, et al. Among authors: brown je. Curr Opin Support Palliat Care. 2010 Sep;4(3):189-94. doi: 10.1097/SPC.0b013e32833d3024. Curr Opin Support Palliat Care. 2010. PMID: 20671553 Review.

7

Skeletal complications and survival in renal cancer patients with bone metastases.

Woodward E, Jagdev S, McParland L, Clark K, Gregory W, Newsham A, Rogerson S, Hayward K, Selby P, Brown J. Woodward E, et al. Bone. 2011 Jan;48(1):160-6. doi: 10.1016/j.bone.2010.09.008. Epub 2010 Sep 18. Bone. 2011. PMID: 20854942

8

Zoledronic acid.

Coleman R, Burkinshaw R, Winter M, Neville-Webbe H, Lester J, Woodward E, Brown J. Coleman R, et al. Expert Opin Drug Saf. 2011 Jan;10(1):133-45. doi: 10.1517/14740338.2011.540387. Epub 2010 Nov 29. Expert Opin Drug Saf. 2011. PMID: 21114419 Review.

9

Skeletal metastasis in renal cell carcinoma: current and future management options.

Wood SL, Brown JE. Wood SL, et al. Among authors: brown je. Cancer Treat Rev. 2012 Jun;38(4):284-91. doi: 10.1016/j.ctrv.2011.06.011. Epub 2011 Jul 29. Cancer Treat Rev. 2012. PMID: 21802857 Review.

10

Serum lactate dehydrogenase is prognostic for survival in patients with bone metastases from breast cancer: a retrospective analysis in bisphosphonate-treated patients.

Brown JE, Cook RJ, Lipton A, Coleman RE. Brown JE, et al. Clin Cancer Res. 2012 Nov 15;18(22):6348-55. doi: 10.1158/1078-0432.CCR-12-1397. Epub 2012 Sep 4. Clin Cancer Res. 2012. PMID: 22952345

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

755 results

Search Page